Aarti Drugs Ltd

Aarti Drugs Ltd

Aarti Drugs Ltd has announced the results of its 41st Annual General Meeting (AGM), where shareholders voted on various resolutions, including the appointment of new directors and the retirement of existing directors.

Aarti Drugs Ltd

Aarti Drugs Ltd has made a presentation to its shareholders at the 41st Annual General Meeting, highlighting its business overview, leadership in API manufacturing, and diversified presence across segments.

Aarti Drugs Ltd

Aarti Drugs Ltd held its 41st Annual General Meeting (AGM) on September 26, 2026, through video conferencing. The meeting saw the appointment of new directors, including Nilesh Bhalchandra Patil and Adhish Prakash Patil, and the re-appointment of existing directors. The company also approved the payment of profit-related commission to non-executive directors and granted stock options under the 'Aarti Drugs Limited Performance Stock Option Plan 2026'.

Aarti Drugs Ltd

Aarti Drugs Ltd has published a newspaper advertisement announcing the completion of dispatch of its Annual Report for the Financial Year 2025-26 and the Notice of the 41st Annual General Meeting scheduled for September 26, 2026.

Aarti Drugs Ltd

Aarti Drugs Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, as required by SEBI regulations.

Aarti Drugs Ltd

Aarti Drugs Ltd announced its 41st Annual General Meeting (AGM) scheduled for September 26, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The AGM notice along with the Annual Report for FY 2025-26 is available on the company's website.

Aarti Drugs Ltd

Aarti Drugs Ltd has released its Annual Report for FY 2025-26, highlighting key highlights of the year, including the commencement of commercial production at the Sayakha facility, expansion of regulated market revenues, and securing key global regulatory approvals.

Aarti Drugs Ltd

Aarti Drugs Ltd announced publication of newspaper advertisement for its 41st Annual General Meeting scheduled on September 26, 2026, through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).

Aarti Drugs Ltd

Aarti Drugs Ltd has approved the 'Aarti Drugs Limited Performance Stock Option Plan 2026' to grant up to 8,00,000 performance stock options to eligible employees, subject to member approval.

Aarti Drugs Ltd

Aarti Drugs Ltd has announced the closure of its trading window from August 25, 2026, to August 29, 2026, due to a board meeting scheduled on August 27, 2026, to consider the 'Aarti Drugs Limited – Performance Stock Option Plan 2026'.

Aarti Drugs Ltd

Aarti Drugs Ltd has scheduled a Board of Directors meeting on August 27, 2026, to consider and approve the 'Aarti Drugs Limited - Performance Stock Option Plan 2026'. The trading window will be closed from August 25 to August 29, 2026.

Aarti Drugs Ltd

Aarti Drugs Ltd has announced an analyst/institutional investor meet on August 20, 2026, in Mumbai, where company officials will discuss publicly available information without sharing unpublished price sensitive information.

Aarti Drugs Ltd

Aarti Drugs Ltd has informed that the Hon'ble Supreme Court of India has dismissed the Special Leave Petition filed by the GST Department, disposing of the matter in favor of the company.

Aarti Drugs Ltd

Aarti Drugs Ltd reported a strong start to the financial year with improved API realizations and volume growth across key products, driven by healthy demand across API and Spec Chem portfolio, and continued traction in both domestic and international markets.

Aarti Drugs Ltd

Aarti Drugs Ltd has informed the stock exchanges about an analyst/institutional investors meeting to be held on August 10, 2026, at Nirmal Bang Trident BKC, Mumbai. The meeting will be held from 11:00 AM to 1:00 PM, and discussions will be based on publicly available information.

Aarti Drugs Ltd

Aarti Drugs Ltd has uploaded the audio recording of its Q1FY27 earnings conference call on its website, accessible via a provided link.

Aarti Drugs Ltd

Aarti Drugs Ltd has published its standalone and consolidated financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, through newspaper publications in Financial Express (English) and Pratahkal (Marathi) on August 2, 2026.

Aarti Drugs Ltd

Aarti Drugs Ltd has announced its Q1FY27 investor presentation, highlighting a strong operational and financial performance with a 19% YoY revenue growth, 30% YoY EBITDA growth, and 35% YoY PBT growth. The company's API and Speciality Chemicals portfolio saw improved realizations and volume growth, contributing to the robust quarter.

Aarti Drugs Ltd

Aarti Drugs Ltd reported its Q1FY27 business and financial performance, with revenue growing 19% YoY to Rs. 703.6 crore, EBITDA increasing 30% YoY to Rs. 96.9 crore, and EBITDA margin expanding 120 bps to 13.8%. The company's CFO & COO, Mr. Adhish Patil, attributed the strong performance to a mix of volume growth and improved realizations across its API & Speciality Chemicals portfolio, as well as disciplined execution.

Aarti Drugs Ltd

Aarti Drugs Ltd has received a revocation order from the Gujarat Pollution Control Board (GPCB) related to a closure direction issued for its plant located at Sayakha. The GPCB has accepted the company's application and has issued a revocation order, thereby permitting the company to continue its operations. An interim Environmental Damage Compensation (EDC) of Rs. 10,20,000/- has been levied as per the "Polluter Pays" Principle.